KRAS and cancer: Early data about BI1701963, presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, led to an ongoing phase I clinical trial that is exploring this drug both as monotherapy and in combination with trametinib in patients with advanced, KRAS+, solid tumors (NCT04111458).